Last reviewed · How we verify
Placebo to interferon beta-1a
Interferon beta-1a activates interferon signaling pathways to modulate immune responses and reduce inflammatory activity.
Interferon beta-1a activates interferon signaling pathways to modulate immune responses and reduce inflammatory activity. Used for Relapsing-remitting multiple sclerosis, Secondary progressive multiple sclerosis.
At a glance
| Generic name | Placebo to interferon beta-1a |
|---|---|
| Sponsor | Celgene |
| Drug class | Interferon |
| Target | Interferon-beta receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Interferon beta-1a is a recombinant cytokine that binds to interferon-beta receptors on immune cells, triggering intracellular signaling cascades that enhance natural killer cell activity, increase antigen presentation, and promote anti-inflammatory cytokine production. This mechanism helps suppress autoreactive T cells and reduce demyelination in multiple sclerosis by shifting the immune response toward a more regulatory phenotype.
Approved indications
- Relapsing-remitting multiple sclerosis
- Secondary progressive multiple sclerosis
Common side effects
- Flu-like symptoms (fever, chills, myalgia)
- Injection site reactions
- Headache
- Elevated liver enzymes
- Lymphopenia
- Depression
Key clinical trials
- Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis (PHASE3)
- A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (PHASE2)
- Trial of Treatments for COVID-19 in Hospitalized Adults (PHASE3)
- Early Interferon-beta Treatment for West-Nile Virus Infection (PHASE2)
- Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products (PHASE1)
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (PHASE3)
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (PHASE3)
- Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to interferon beta-1a CI brief — competitive landscape report
- Placebo to interferon beta-1a updates RSS · CI watch RSS
- Celgene portfolio CI